FR2285855A1 - 2,2'-Anhydro-1-beta-D-arabinofuranosyl-cytosine salts prepns - obtd by freeze drying aq solns. contg specified additives, for parenteral leukaemia treatment - Google Patents

2,2'-Anhydro-1-beta-D-arabinofuranosyl-cytosine salts prepns - obtd by freeze drying aq solns. contg specified additives, for parenteral leukaemia treatment

Info

Publication number
FR2285855A1
FR2285855A1 FR7432321A FR7432321A FR2285855A1 FR 2285855 A1 FR2285855 A1 FR 2285855A1 FR 7432321 A FR7432321 A FR 7432321A FR 7432321 A FR7432321 A FR 7432321A FR 2285855 A1 FR2285855 A1 FR 2285855A1
Authority
FR
France
Prior art keywords
prepns
solns
contg
arabinofuranosyl
anhydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7432321A
Other languages
French (fr)
Other versions
FR2285855B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kohjin Holdings Co Ltd
Kohjin Co
Original Assignee
Kohjin Holdings Co Ltd
Kohjin Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kohjin Holdings Co Ltd, Kohjin Co filed Critical Kohjin Holdings Co Ltd
Priority to FR7432321A priority Critical patent/FR2285855A1/en
Publication of FR2285855A1 publication Critical patent/FR2285855A1/en
Application granted granted Critical
Publication of FR2285855B1 publication Critical patent/FR2285855B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Abstract

Freeze-dried prepns. contg. 2,2'-anhydro-1-beta-D-arabinofuranosyl-cytosine salts (I) are prepd. by freeze-drying an aq. soln. of (I) contg. (a) 0.1-6 wt.%, based on (I), of a saccharide, (b) 0.1-6 wt.% of polyvinylpyrrolidone (PVP), (c) 0.1-6 wt.% of sodium carboxymethylcellulose (NaCMC) and/or (d) 0.01-0.05 wt.% of a nonionic wetting agent. The products can be used to prepare injectable solns. for use in leukaemia treatment. The prepns. have good storage stability, can be prepd. by conventional rapid freeze-drying, and have a water-solubility of >=1 g/10 ml, forming clear solns.
FR7432321A 1974-09-25 1974-09-25 2,2'-Anhydro-1-beta-D-arabinofuranosyl-cytosine salts prepns - obtd by freeze drying aq solns. contg specified additives, for parenteral leukaemia treatment Granted FR2285855A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7432321A FR2285855A1 (en) 1974-09-25 1974-09-25 2,2'-Anhydro-1-beta-D-arabinofuranosyl-cytosine salts prepns - obtd by freeze drying aq solns. contg specified additives, for parenteral leukaemia treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7432321A FR2285855A1 (en) 1974-09-25 1974-09-25 2,2'-Anhydro-1-beta-D-arabinofuranosyl-cytosine salts prepns - obtd by freeze drying aq solns. contg specified additives, for parenteral leukaemia treatment

Publications (2)

Publication Number Publication Date
FR2285855A1 true FR2285855A1 (en) 1976-04-23
FR2285855B1 FR2285855B1 (en) 1978-07-28

Family

ID=9143415

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7432321A Granted FR2285855A1 (en) 1974-09-25 1974-09-25 2,2'-Anhydro-1-beta-D-arabinofuranosyl-cytosine salts prepns - obtd by freeze drying aq solns. contg specified additives, for parenteral leukaemia treatment

Country Status (1)

Country Link
FR (1) FR2285855A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0012523A1 (en) * 1978-11-20 1980-06-25 American Home Products Corporation Therapeutic compositions with enhanced bioavailability and process for their preparation
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
FR2577437A1 (en) * 1985-02-21 1986-08-22 Corbiere Jerome New process for dissolving chemical compounds and aqueous preparations thus obtained
EP0306312A1 (en) * 1987-09-01 1989-03-08 Yamanouchi Pharmaceutical Co. Ltd. Lyophilized pharmaceutical composition of neocarzinostatin derivative
EP0317281A2 (en) * 1987-11-19 1989-05-24 The Wellcome Foundation Limited Pharmaceutical formulations containing melphalan or melphalan hydrochloride, as well as melphalan and melphalan hydrochloride and processes for preparing them

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3397268A (en) * 1965-09-01 1968-08-13 Upjohn Co Process of treating herpes simplex with 1-beta-d-arabinofuranosylcytosine
US3444294A (en) * 1961-01-23 1969-05-13 Upjohn Co Aiding the regression of acute leukemia with 1 - beta - d - arabinofuranosylcytosine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3444294A (en) * 1961-01-23 1969-05-13 Upjohn Co Aiding the regression of acute leukemia with 1 - beta - d - arabinofuranosylcytosine
US3397268A (en) * 1965-09-01 1968-08-13 Upjohn Co Process of treating herpes simplex with 1-beta-d-arabinofuranosylcytosine

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0012523A1 (en) * 1978-11-20 1980-06-25 American Home Products Corporation Therapeutic compositions with enhanced bioavailability and process for their preparation
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
FR2577437A1 (en) * 1985-02-21 1986-08-22 Corbiere Jerome New process for dissolving chemical compounds and aqueous preparations thus obtained
EP0306312A1 (en) * 1987-09-01 1989-03-08 Yamanouchi Pharmaceutical Co. Ltd. Lyophilized pharmaceutical composition of neocarzinostatin derivative
US5026772A (en) * 1987-09-01 1991-06-25 Yamanouchi Pharmaceutical Co., Ltd. Lyophilized pharmaceutical composition of neocarzinostatin derivative
EP0317281A2 (en) * 1987-11-19 1989-05-24 The Wellcome Foundation Limited Pharmaceutical formulations containing melphalan or melphalan hydrochloride, as well as melphalan and melphalan hydrochloride and processes for preparing them
EP0317281A3 (en) * 1987-11-19 1989-08-09 The Wellcome Foundation Limited Pharmaceutical formulations containing melphalan or melphalan hydrochloride, as well as melphalan and melphalan hydrochloride and processes for preparing them
US4997651A (en) * 1987-11-19 1991-03-05 Poole Stephen W Pharmaceutical formulations

Also Published As

Publication number Publication date
FR2285855B1 (en) 1978-07-28

Similar Documents

Publication Publication Date Title
ES368496A1 (en) Aqueous doxycycline compositions
GB1401585A (en) Buffered smoking substitute compositions
IE45026L (en) Veterinary compositions
IE40663L (en) Oxytetracycline solutions
FR2285855A1 (en) 2,2'-Anhydro-1-beta-D-arabinofuranosyl-cytosine salts prepns - obtd by freeze drying aq solns. contg specified additives, for parenteral leukaemia treatment
FR1337806A (en) Cylinder and in particular calender cylinder for the pressure treatment of strip articles
OA03170A (en) Baker's yeast, dried and active, and process for its preparation.
CA936533A (en) 5-aryl-2,3-dihydro-2,2(or 3,3) dimethyl-5h-imidazo(2,1-a) isoindol-5-ols and 2(4,4(5,5) dimethyl-2-imidazolin-2-yl) bensophenone acid addition salts and processes for their preparation
ES426414A1 (en) Method to produce a preparation of dry cyclycytden by freezing. (Machine-translation by Google Translate, not legally binding)
JPS5233269A (en) Skid rails having stoppers to prevent collision between pipes
ES2010559A6 (en) Topical process for treating herpes infections using 5-isopropyl-2'- beta -deoxyuridine as the active agent
GB1295571A (en)
NL7510490A (en) PROCESS FOR PREPARING ANTHELMINTIC ACTIVE, BASICALLY SUBSTITUTED 2-CARBALKO-XYAMINO-BENZIMIDAZOLYL-5 (6) PHENYL ETHERS AND KETONES.
USD242750S (en) Vented hair brush block or similar article
GB1384488A (en) Stabilized n6-2,0-dibutyryladenosine-3,5,-cyclic phosphate salts and production thereof
FR2092785A1 (en) 2-azaquinolizidine derivs and salts neurotropic and anti - -histamine agents synthesis
SU432098A1 (en)
GB1448582A (en) Baths
Patel et al. DERIVATIVES OF THIOUREA AS CORROSION INHIBITORS FOR BRASS IN NITRIC ACID SOLUTION
BE775703A (en) PERFECTED PROCESS FOR OBTAINING ACTIVE CARBON
ES431758A1 (en) Method to produce a preparation of dry cyclicystine salt by freezing. (Machine-translation by Google Translate, not legally binding)
Schippert The Influence of Tensioning Force on Forward Slipping in the Cold Rolling of Strip
KRALL et al. LATEST DEVELOPMENTS IN HORIZONTAL CONTINUOUS CASTING OF NON-FERROUS STRIP AND SECTIONS
ES389832A1 (en) Procedure for the obtaining of new derivatives of organic nitrogenated bases of prolonged action. (Machine-translation by Google Translate, not legally binding)
KR790000168B1 (en) Salts of 2,6-dioxocyclohexane thiocarboxylic acid 4'-halo-anilides and pharmaceutical compositions

Legal Events

Date Code Title Description
ST Notification of lapse